GlassScriptPhysician profile
Christine Law
NPI 1023022761
$15,576.87
in general payments reported to CMS, 2019-2025
32 companies · $2,327 in 2025
The $2,327 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,409 · 2020: $525 · 2021: $1,437 · 2022: $2,361 · 2023: $2,090 · 2024: $2,427 · 2025: $2,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,639 · Education: $160 · Grant: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,639.17 |
| Education | $160.44 |
| Grant | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,810.33 | 2019-2022 | |
| Abbvie INC. | $3,221.27 | 2019-2025 | |
| Merz North America, INC. | $2,036.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $805.50 | 2019-2025 | |
| Galderma Laboratories, L.P. | $783.29 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Regeneron Healthcare Solutions, INC. | $642.15 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $560.83 | 2022-2025 | Sotyktu |
| Pfizer INC. | $526.12 | 2019-2025 | |
| Genzyme Corporation | $446.41 | 2020-2025 | |
| Janssen Biotech, INC. | $370.24 | 2019-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $287.70 | 2019-2025 | |
| Incyte Corporation | $286.49 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $242.44 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $227.24 | 2019-2025 | Ebglyss, Taltz, Zepbound |
| Amgen INC. | $217.81 | 2022-2024 | Otezla, Enbrel |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $196.58 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $165.81 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $164.40 | 2022-2024 | Vtama |
| Ucb, INC. | $148.32 | 2022-2025 | Bimzelx |
| Almirall LLC | $115.45 | 2019-2024 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.57 | 2022-2024 | Spevigo, Cyltezo |
| Botanix Sb INC | $60.12 | 2025 | Sofdra |
| Journey Medical Corporation | $45.63 | 2019 | |
| Novum Pharma, LLC | $25.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.83 | 2023 | Ycanth |
| Revance Therapeutics, INC. | $18.93 | 2025 | Daxxify |
| Fidia Pharma USA INC. | $16.54 | 2024 | Hyalgan, Hymovis, Triluron |
| Kyowa Kirin, INC. | $16.07 | 2025 | |
| Prugen, INC. Pharmaceuticals | $15.53 | 2019 | |
| Aclaris Therapeutics, INC. | $14.65 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.66 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.